Chemoimmunotherapy in Stages III & IV Ovarian and Endometrial Carcinoma Adriamycin + Cyclophosphamide vs. Adriamycin + Cyclophosphamide + BCG
Publication Information Expand/Collapse
2009
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
Minority report: how best to analyze clinical trial data to address disparities
1982
A randomized trial of Doxorubicin and Cyclophosphamide + BCG vs. Doxorubicin and Cyclophosphamide therapy of advanced ovarian cancer.
1980
Randomized trial of chemotherapy versus chemo- immunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest Oncology Group study.
1979
Randomized study of chemoimmunotherapy for advanced ovarian carcinoma. A preliminary report of a Southwest Oncology Group study.
Chemoimmunotherapy for advanced ovarian carcinoma with adriamycin cyclophosphamide + BCG: Early report of a Southwest Oncology Group study.
BCG as an adjuvant to Adriamycin-Cyclophosphamide in the treatment of advanced ovarian carcinoma: Ongoing analysis of a Southwest Oncology Group study.
BCG as an adjuvant to adriamycin - cytoxan for advanced ovarian cancer.
1978
Chemoimmunotherapy for advanced ovarian carcinoma with adriamycin-cyclophosphamide + BCG: Early report of a Southwest Oncology Group study.
1977
Adjuvant immunotherapy with BCG of advanced ovarian cancer: A preliminary report.